About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

NCT01210495·77 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pfizer

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Locally advanced or metastatic HCC
Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib.
Child-Pugh Class A or B (score 7 only) disease.

You may not be if

Prior treatment of advanced HCC with more than one prior first-line systemic therapy.
Any prior local therapy within 2 weeks of starting the study treatment.
Presence of hepatic encephalopathy and/or clinically relevant ascites.
Presence of main portal vein invasion by HCC.

The record

StatusCompleted

PhasePhase 2

Taking part224

StartedDec 2010

UpdatedJan 9, 2019

Conditions

Hepatocellular Carcinoma

Where77

Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, United States
UCSD Medical Center- La Jolla
La Jolla, California, United States
Moores UCSD Cancer Center
La Jolla, California, United States

Clareo Health | Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma